{
    "Trade/Device Name(s)": [
        "VITEK\u00ae 2 AST-GN Ciprofloxacin"
    ],
    "Submitter Information": "bioM\u00e9rieux, Inc.",
    "510(k) Number": "K162737",
    "Predicate Device Reference 510(k) Number(s)": [
        "K121546"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON"
    ],
    "Summary Letter Date": "May 17, 2017",
    "Summary Letter Received Date": "May 18, 2017",
    "Submission Date": "September 29, 2016",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully automated short-term incubation cycle antimicrobial susceptibility system"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Ciprofloxacin"
    ],
    "Specimen Type(s)": [
        "Gram negative bacilli (isolated colonies)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "VITEK\u00ae 2",
        "VITEK\u00ae 2 Compact"
    ],
    "Method(s)/Technology(ies)": [
        "Antimicrobial susceptibility testing",
        "Microdilution"
    ],
    "Methodologies": [
        "Minimum inhibitory concentration (MIC) determination"
    ],
    "Submission Type(s)": [
        "Reagent",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for VITEK\u00ae 2 AST-GN Ciprofloxacin antimicrobial susceptibility testing system for Gram negative bacilli",
    "Indications for Use Summary": "Quantitative antimicrobial susceptibility testing of Gram negative bacilli using VITEK\u00ae 2 and VITEK\u00ae 2 Compact Systems as a laboratory aid for in vitro susceptibility determination to ciprofloxacin.",
    "fda_folder": "Microbiology"
}